검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adjuvant Immunoradiotherapy (ARM1, Adjuvant Immunoradiotherapy, Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)) University of Manitoba·Esophageal Cancer 35 trials |
|---|---|
Overview Program | Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B) |
Overview Company | University of Manitoba |
Overview Modality | ANTIBODY |
Overview Target | Esophageal Cancer |
Overview Indication | Esophageal Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Biomarker | biomarkers like PD-L1 and TMB, alongside emerging tools such as liquid biopsy (ctDNA), are essential for pati |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial.. Folic acid is routinely co-administered with methotrexate (MTX) to reduce toxicity; however, the optimal dose remains unclear. This study investigated whether increasing … |
Clinical OS | 12.9 |
Clinical Result source | ClinicalTrials.gov NCT03894891 |
Clinical Data Tier / Score | A · 32 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adjuvant Immunoradiotherapy (ARM1, Adjuvant Immunoradiotherapy, Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)) University of Manitoba·Esophageal Cancer 35 trials |
|---|---|
Overview Program | Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B) |
Overview Company | University of Manitoba |
Overview Modality | ANTIBODY |
Overview Target | Esophageal Cancer |
Overview Indication | Esophageal Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Biomarker | biomarkers like PD-L1 and TMB, alongside emerging tools such as liquid biopsy (ctDNA), are essential for pati |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial.. Folic acid is routinely co-administered with methotrexate (MTX) to reduce toxicity; however, the optimal dose remains unclear. This study investigated whether increasing … |
Clinical OS | 12.9 |
Clinical Result source | ClinicalTrials.gov NCT03894891 |
Clinical Data Tier / Score | A · 32 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교